Cost of Achieving Combined Improvements in HbA1c and Weight without Hypoglycaemia over 4 Years in a Post-Hoc Analysis of Dapagliflozin + MET Vs Glipizide + MET

The SGLT2 inhibitor dapagliflozin (DAPA) increases glucosuria in an insulin-independent manner resulting in reductions in hyperglycemia, weight and BP with a low risk of hypoglycemia. Glipizide (GLIP) reduces hyperglycemia by increasing beta cell insulin secretion with risk of hypoglycaemia and weight gain. We conducted a cost analysis of treating patients over 4 years to two relevant composite endpoints: (1) HbA1c lowering of ≤0.5%, no major or minor hypoglycaemic events and weight loss ≥3% and (2) HbA1c lowering of ≤0.5%, no major or minor hypoglycaemic events and weight loss ≥5%.

Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: P Johansen, J Mukherjee, E Sörstadius, C Sternhufvud Source Type: research